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Abstract: Background: Though not obvious at a first glance, myopathies may be associated with ischemic stroke. Stroke-
like episodes resemble ischemic stroke only to some extent but are a unique feature of certain mitochondrial disorders 
with a pathogenesis at variance from that of ischemic stroke. Only limited data are available about ischemic stroke in pri-
mary myopathies and the management of stroke-like episodes in mitochondrial disorders. This review aims to summarize 
and discuss current knowledge about stroke in myopathies and to delineate stroke-like episodes from ischemic stroke.  
Methods: Literature review via PubMED using the search terms “stroke”, “cerebrovascular”, “ischemic event”, “stroke-
like episode”, “stroke-mimic”, “mitochondrial disorder”. 
Results: Stroke in myopathies is most frequently cardioembolic due to atrial fibrillation or atrial flutter, dilated cardio-
myopathy, or left-ventricular hypertrabeculation (noncompaction). The second most frequent cause of stroke in 
myopathies is angiopathy from atherosclerosis or vasculitis, which may be a feature of inflammatory myopathies. Athero-
sclerosis may either result from classical risk factors, such as diabetes, arterial hypertension, hyperlpidemia, or smoking, 
associated with muscle disease, or may be an inherent feature of a mitochondrial disorder. In case of severe heart failure 
from cardiomyopathy as a manifestation of muscle disease low flow infarcts may occur. Thrombophilic stroke has been 
described in polymyositis and dermatomyositis in association with anti-phospholipid syndrome. Stroke-like episodes oc-
cur particularly in mitochondrial encephalopathy, lactacidosis and stroke-likeepisode syndrome but rarely also in Leigh-
syndrome and other mitochondrial disorders. Stroke-like episodes are at variance from ischemic stroke, pathogenically, 
clinically and on imaging. They may be the manifestation of a vascular, metabolic or epileptic process and present with 
predominantly vasogenic but also cytotoxic edema on MRI. Differentiation between ischemic stroke and stroke-like epi-
sodes is essential in terms of management and prognosis. Management of ischemic stroke in patients with myopathy is not 
at variance from the treatment of ischemic stroke in non-myopathic patients. There is no standardized treatment of stroke-
like episodes but there is increasing evidence that these patients profit from the administration of L-arginine and conse-
quent antiepileptic treatment if associated with seizure activity. 
Conclusions: Ischemic stroke may be a complication of myopathy and needs to be delineated from stroke-like episodes, 
which are unique to mitochondrial disorders, particularly mitochondrial encephalopathy, lactacidosis and stroke-
likeepisode syndrome. Ischemic stroke in myopathies is most frequently cardioembolic and treatment is not at variance 
from non-myopathic ischemic stroke. Treatment of stroke-like episodes is not standardized but seems to respond to L-
arginine and adequate antiepileptic treatment. 
Keywords: Cerebral infarction, ischemic stroke, genetics, cardiomyopathy, noncompaction, atrial fibrillation, neuromuscular 
disorder, MELAS-syndrome, stroke-like episode. 
INTRODUCTION 
  Myopathies are a heterogeneous group of neurological 
disorders primarily affecting the striated skeletal muscle due 
to mutations in genes encoding for components of the myo-
cyte (primary myopathies) or due to secondary affection of 
the muscle within the scope of a general disorder primarily 
affecting organs other than the muscle (secondary myopa-
thies). Ischemic stroke is one of the most prevalent neuro-
logical disorders and the third most frequent cause of death 
[1]. Stroke-like episodes (SLEs) are phenotypic features 
predominantly of mitochondrial disorders (MIDs), most   
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frequently mitochondrial encephalopathy, lactacidosis, SLE 
(MELAS)-syndrome, and mimic the clinical manifestations 
of ischemic stroke to some extent [2]. Their prevalence is 
much lower than that of ischemic stroke. Though myopathies 
do not seem to be obviously associated with stroke at a first 
glance, there is a strong causal relation if there is cardiac 
involvement in myopathies, if the underlying cause of 
myopathy is a MID, or if the muscle disease is part of a mul-
tisystem disease, which also manifests with classical risk 
factors for ischemic stroke, such as diabetes, hyper-
lipidemia, or arterial hypertension. This review aims to give 
an overview about the current knowledge concerning the 
relation between muscle disease and ischemic stroke and 
SLEs with regard to pathogenesis, diagnosis, treatment and 
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CLASSIFICATION OF ISCHEMIC STROKE  
  Ischemic stroke is generally graded according to the 
TOAST-classification, which denotes five subtypes of is 
chemic stroke following its pathogenesis: 1) atherosclerosis 
of large arteries 2) cardioembolism, 3) small-vessel occlu-
sion, 4) stroke due to other etiology (vasculitis, dissection, 
coagulation disorder etc.), and 5) stroke of undetermined 
etiology [3]. Narrowing or occlusion of large extra- or intra-
cerebral arteries by arteriopathy or embolism leads to ische-
mia of the downstream vascular territory. Narrowing or 
occlusion of small intra-cerebral arteries by arteriopathy or 
embolism leads to ischemia only of a small vascular terri-
tory, morphologically manifesting as white matter lesions or 
lacunas. In addition to cardioembolic or angiopathic causes, 
ischemic stroke may result from hemodynamic, thrombo-
philic, or metabolic abnormalities [4].  
RISK FACTORS FOR STROKE IN MYOPATHIES  
  Risk factors for the development of ischemic stroke in 
myopathies are cardiac disease, frequently associated with 
myopathies, or atherosclerosis either due to classical risk 
factors from a multisystem disease or due to a manifestation 
of a MID [5]. Other risk factors may be low output failure, 
arterial hypotension or thrombophilic conditions. Predispos-
ing for stroke may be also MELAS-syndrome, which is 
pathogenically characterised by arteriopathy [6] and fre-
quently also presents with metabolic muscle disease or com-
promised cardiac function. Cardiac involvement predispos-
ing for ischemic stroke includes sarrhythmias, such as atrial 
fibrillation, heart failure from hypertrophic cardiomoypathy, 
dilative cardiomyopathy, restrictive cardiomoypathy, or 
noncompaction without heart failure. Another risk factor for 
ischemic stroke may be cryptogenic intraventricular throm-
bus formation in the absence of atrial fibrillation or heart 
failure, as has been described in Duchenne muscular dystro-
phy (DMD) [7]. 
ETIOLOGY OF ISCHEMIC STROKE IN 
MYOPATHIES  
A) Cardioembolism 
  Cardiac disease is a frequent feature of many of the pri-
mary muscle disorders. Cardiac involvement in myopathies 
may manifest as cardiac conduction disorder or cardio-
myopathy. Conduction disorders may manifest as impulse 
generation or impulse conduction abnormality. 
1. Atrial Fibrillation/Flutter 
  The arrhythmia most frequently associated with stroke in 
myopathies is atrial fibrillation. Impaired contractility of the 
left atrial wall favors thrombus formation within the left 
Table 1.  Myopathies in which Atrial Fibrillation or Atrial Flutter has been Found 
Myopathy Reference  Stroke 
Primary myopathies 
 Muscular  dystrophies   
  Dystrophinopathies  [9,10,12]  [9,10] 
    Emery-Dreifuss muscular dystrophy 1 (emerin)  [8]  [8] 
    Emery-Dreifuss muscular dystrophy 2 (laminA/C)  [8]  [8] 
    Limb girdle muscular dystrophies   
     LGMD1B  [76-81]  NR 
    Myotonic  dystrophies   
       Myotonic dystrophy 1  [12,82-84]   [11,12] 
       Myotonic dystrophy 2  [13]  [13] 
  Facio-scapulo-humeral  muscular dystrophy  [85]  NR 
  Myofibrillar  myopathies  [86]  NR 
   Desmin  myopathy      [87,88]    NR 
    Rigid spine syndrome      [89]   NR 
 Danon’s  disease      [90]    [90] 
  Barth  syndrome  [4]  NR 
  McLeod  syndrome  [91,92]  NR 
 Congenital  myopathies  [93]  NR 
 Metabolic  myopathies     
    Glycogenosis  [94]  NR 
    Mitochondrial  myopathy  [95]  NR 
  Congenital fiber type dysproportion    [96]    NR 
  Epidermiolysis bullosa simplex  [97]  NR 
Secondary myopathies 
 Polymyositis  [98]  NR 
 Dermatomyositis  [14]  [14] 
 Colchicine-induced  myopathy  [99]  NR 
 Hypothyroid  myopathy  [100]  NR 
 Hyperthyroid  myopathy  [101]  NR 
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atrium or the left atrial appendage, which are consecutively 
flushed out to the arterial bed, including the cerebral arteries. 
Myopathies in which atrial fibrillation has been described are 
listed in Table 1. That stroke has not been reported in each of 
the myopathies listed in this table may be due to the poor 
follow-up of most myopathy patients. In a series of 11 pa-
tients with Emery-Dreyfuss muscular dystrophy ischemic 
stroke has been reported in four of them who presented with 
atrial fibrillation or flutter. The outcome was not reported but 
three of these patients had autosomal dominant (Lamin A/C) 
and one X-linked (emerin) Emery-Dreyfuss muscular dys-
trophy [8]. Stroke was also reported during an episode of 
atrial fibrillation in a patient with Becker muscular dystrophy 
[9]. Among five patients with DMD, one experienced 
ischemic stroke [10]. He had a history of atrial fibrillation 
but also of dilative cardiomyopathy. Transient ischemic 
attack and stroke have been also described in a patient with 
myotonic dystrophy 1 in whom paroxysmal atrial fibrillation 
was recorded [11]. Screening of 52 patients with DMD, 61 
with myotonic dystrophy 1 and 14 with Becker muscular 
dystrophy revealed atrial flutter in 3 with MD1, and 1 with 
DMD. Atrial fibrillation was detected in none of them. Only 
one of the included patients developed ischemic stroke dur-
ing atrial flutter [12]. In a study on 38 patients with myotonic 
dystrophy 2, five had developed ischemic stroke. Two of 
these patients had atrial fibrillation with normal systolic 
function [13]. Ischemic stroke may be associated also with 
secondary myopathy. In a patient with dermatomyositis, 
restrictive cardiomyopathy, and atrial fibrillation, a transient 
ischemic attack has been reported [14]. Arrhythmias leading 
to cardioembolism may also result from hyperkaliemia fol-
lowing rhabdomyolysis.  
2. Dilative Cardiomyopathy 
  Dilative cardiomyopathy is prone to heart failure and 
arrhythmias [15]. Thus patients with myopathy in whom 
cardiac involvement manifests as dilative cardiomyopathy 
are also at increased risk to thromboembolism. Though the 
exact pathogenesis of the intracardiac thrombus formation in 
dilative cardiomyopathy remains elusive it can be speculated 
that impaired hemodynamics activates the coagulation cas-
cade. In addition to embolism, dilative cardiomyopathy may 
be associated with arterial hypotension and thus cerebral 
hypoperfusion. Studies about myopathies with dilative car-
diomyopathy which were associated with stroke are listed in 
Table 2. According to these studies ischemic stroke has been 
reported in two patients with DMD [16]. Both patients ex-
perienced ischemic stroke at age 21y in sinusrhythm but with 
an ejection fraction (EF) below 20% and together with in-
creased thrombin-ATIII complexes and increased D-dimer. 
Table 2.  Myopathies Associated with Dilative Cardiomyopathy and Stroke 
Myopathy Reference  Stroke 
Muscular dystrophies 
 Dystrophinopathies    [16,102]    [10,16,17]   
  Limb girdle muscular dystrophies  [103,104]  NR 
   Laminopathies  [81,105-107]  NR 
   LGMD1B  [108]  NR 
   LGMD1E  [108]  NR 
   LGMD2D-F  [108]  NR 
   LGMD2I  [108,109]  NR 
 Congential  muscular  dystrophies   
    Fukuyama type CMD  [110]  NR  
   Merosin-deficient  CMD  [111]  NR 
 Myofibrillar  myopathies  [112]  NR 
   Desminopathy  [113]  NR 
 Other   
   Vacuolar  myopathy  (LAMP2)  [114,115]  NR   
   Barth  syndrome  [116,117]  [18] 
   McLeod  syndrome  [118]  NR 
   Reducing  body  myopathy  [119,120]  NR 
Congenital myopathies 
 Nemaline  myopathy  [121,  122]  NR 
  Central core disease  [123]  NR 
 Centronuclear  myopathy  [124,125]  NR 
  Congenital fiber type dysproportion  [96,126,127]  NR 
Metabolic myopathies 
 Glycogenosis  type  IV  [128]  NR 
  Primary carnitin deficiency [129]  NR 
 Mitochondrial  disorders  [130,131]  NR 
 Kearns-Sayre  syndrome  [132]  NR 
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The second patient had experienced a TIA already five 
months prior to the stroke. Ischemic stroke was also reported 
in a 13yo DMD patient in sinusrhythm and with an EF of 35-
40% [17]. Five months later he experienced a second stroke 
in the same vascular territory as before [17]. Stroke was also 
reported in another five patients with DMD and dilative 
cardiomyopathy aged 16-20y of whom one presented with 
atrial fibrillation on ECG [10]. Additionally, stroke has been 
described in a patient with Barth syndrome and dilative car-
diomyopathy who was in sinusrhythm at the time of the 
event [18]. 
3. Left Ventricular Hypertrabeculation (LVHT, Noncom-
paction) 
  LVHT is an increasingly recognized abnormality of the 
left ventricular myocardium, characterised by a two-layered 
structure mainly of the apex and the lateral wall. The epicar-
dial layer consists of normal myocardium whereas the endo-
cardial layer has a spongy-like structure of interwoven myo-
cardial strings, which are all covered with endocardium 
[19,20]. LVHT is most frequently diagnosed on echocardi-
ography if there are more than three single trabeculations at 
end-diastole, if there is the two-layered structure at end-
systole, and if the perfusion of the intertrabecular spaces 
from the ventricular side can be visualized at end-diastole 
[21]. Depending on the study, LVHT is associated with 
myopathy in up to 80% of the cases. Most frequently LVHT 
is associated with Barth syndrome and MIDs [22]. 
Myopathies in which LVHT has been described so far are 
listed in Table 3. Frequent complications of LVHT are heart 
failure, ventricular arrhythmias, and stroke or embolism [22]. 
Though stroke has been reported in a number of LVHT pa-
tients who were not neurologically investigated (Table 4), it 
was described only in two patients with neuromuscular dis-
order and LVHT so far [Finsterer et al., submitted], suggest-
ing that stroke in LVHT patients with myopathy is underes-
timated. One reason for the low rate of stroke in LVHT-
patients with myopathy is that usually LVHT-patients are not 
referred to the neurologist, why a possible neuromuscular 
disorder frequently remains undetected. Whether the stroke 
risk and prevalence of stroke is truly increased in patients 
with LVHT is under debate. There are studies, which do not 
report an increased incidence of stroke among LVHT pa-
tients [23-25], whereas others do [26-29]. In a study on 229 
patients with LVHT but without atrial fibrillation or flutter 
four experienced ischemic stroke during a mean follow-up of 
7.3y [23]. In a study on 62 LVHT patients the incidence of 
stroke was 10% compared to 15% in controls matched for 
age, sex and systolic function [24]. Arguments for an in-
creased stroke risk are that reduced perfusion of intertrabecu-
lar spaces, occurrence of ventricular arrhythmias, and in-
creased incidence of heart failure favor thrombus formation. 
Nevertheless, there is no general need to put LVHT patients 
on oral anticoagulation (OAC) unless classical indications 
for OAC are present. 
B) Macroangiopathy  
1. Atherosclerosis 
  In a patient with MELAS-syndrome due to the hetero-
plasmic transition m.617G>A in the tRNA(Phe) gene recur-
rent ischemic strokes occurred, which were accompanied by 
transient occlusion of the middle cerebral, anterior cerebral 
and internal carotid arteries [30]. Strokes were presumably 
attributed to artery-to-artery embolisms originating from the 
carotid artery stenosis [30]. The cause of the carotid internal 
stenosis was not found. Since classical risk factors for 
atherosclerosis were absent, carotid internal artery stenosis 
was attributed to the MID. Atherosclerosis in the absence of 
classical risk factors for macroangiopathy has been also 
reported in other patients with MID [5]. Macroangiopathic 
ischemic stroke must be clearly delineated from SLE, which 
Table 3.  Myopathies Associated with Noncompaction 
Myopathy Reference  Stroke 
Muscular dystrophies 
  Myotonic dystrophy I  [133]  NR 
 Dystrophinopathies  [134]  NR 
 Barth  syndrome  [18]  [18] 
 Zaspopathy  [135]  NR 
 Laminopathies  [136]  NR 
 Dystrobrevinopathies  [137]  NR 
  Oculopharyngeal muscular dystrophy  [138]  NR 
Metabolic myopathies 
  Mitochondrial disorder  [139]  [Finsterer, submitted] 
 Myoadenylate-deaminase  deficiency  [140]  NR 
  Glycogenosis type II (M. Pompe)  [unpublished]  NR 
Non-myopathic 
  Charcot-Marie-Tooth neuropathy type 1A  [141]  NR 
 Friedreich  ataxia  [unpublished]  NR 
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Table 4.  Studies Reporting Stroke in LVHT Patients 
Study  NOP investigated  NOP stroke  Additional findings 
Münkle et al. 2010 [142]  1  1  Severe heart failure 
Mello et al. 2010 [143]  1  1  Chagas disease 
Stöllberger et al. 2010 [144]  1  1  Heart transplantation 
Vatthyam et al. 2009 [145]  1  1  Fatal acute heart failure,  
Steffel et al. 2009 [146]  78  Not reported  Risk of embolism associated with ECG 
Stanton et al. 2009 [147]  30  2  Death only with decreased systolic function 
Sahin & Karsidag 2009 [28]  1  1  None 
Fazio et al. 2009 [26]  1  1  Not reported 
Fazio et al. 2008 [23]  229  4  Decreased systolic function (50% of pat.) 
Finsterer et al. 2008 [24]  104  16 (15%)  At least 1 classical risk factor in 15 pat.  
Sir et al. 2008 [29]  1  1  None 
Oduncu et al. 2008 [27]  1  1  Bivenricular noncompaction 
Baez-Escudero et al. 2008 [148]  1  1  Systolic dysfunction 
Finsterer et al. 2008 [149]    1  1  Stroke-like-episodes, endocarditis   
Nakajima et al. 2007 [150]  1  1  Decreased systolic function 
Celebi et al. 2007 [151]  1  1  Essential thrombocytosis 
Fernandez Sanchez et al. 2006 [152]  1  1  Pregnant women shortly before delivery 
Walpot et al. 2005 [153]    1  1  Not reported  
Stöllberger & Finsterer2005 [25]   62  6  Incidence of stroke lower than in controls 
Hascelik et al. 2003 [154]    1  1  18 months-old girl with elevated factor VIII" 
 
NOP: Number of patients  
is speculated to be microangiopathy-related or due to non-
ischemic neurovascular events [30]. 
2. Vasculitis 
  Vasculitis of the large arteries associated with stroke has 
been particularly reported in inflammatory myopathies, such 
as polymyositis or dermatomyositis. A patient with polymy-
ositis experienced an ischemic stroke and myocardial infarc-
tion shortly after high dose steroids [31]. Whether stroke in 
this patient was due to vasculitis or due to steroid-induced 
diabetic angiopathy remains speculative [31]. Ischemic 
stroke was also reported in a 47yo female with dermatomy-
ositis. Stroke in this patient was attributed to cerebral vascu-
litis, which was confirmed by conventional angiography and 
brain biopsy [32]. Dermatomyositis and vasculitis responded 
favorably to cyclophosphamide [32]. Ischemic stroke was 
additionally reported in a 47yo female under intravenous 
immunoglobulines (IVIG) for dermatomyositis [33]. 
Whether stroke in this patient was truly due to vasculitis or a 
side effect of IVIG remained speculative [33]. Stroke in 
addition to livedo reticularis, recurrent abortions, and mitral 
regurgitation, was also described in a female with polymy-
ositis/dermatomyositis, lupus erythematosus, and antiphos-
pholipid syndrome [34]. In a recent study on patients with 
dermatomyositis or polymyositis cerebrovascular events 
were found in 0.51% of the cases. Arterial hypertension and 
hyperlipidemia were positive predictors of these events, 
while non-steroid treatment was inversely related with the 
incidence of cerebrovascular events. 
C) Small Vessel Disease 
  Whether there is truly microangiopathy in patients with 
MELAS-syndrome remains speculative. Though there are 
some indications that small vessels are affected in MELAS-
patients, no patients with myopathy and stroke exclusively 
attributable to micrangiopathy have been reported so far. 
Nevertheless, one pathogenetic concept to explain the occur-
rence of SLEs relies on the speculation that MELAS-
syndrome is an angiopathy which also affects the cerebral 
arteries and subsequently causes ischemia. Small vessel 
disease may also occur in HIV-infection, which may not 
only go along with myositis but also with endothelial dys-
function and hyperlipidemia.  
D) Stroke of Other Determined Etiology 
  In a single patient with DMD but without a history of 
atrial fibrillation or heart failure ischemic stroke occurred 
due to embolisation of an intracardiac thrombus [7]. The 
cause of thrombus formation in this patient, however, re-
mained elusive. In a single patient with Kearns-Sayre syn-
drome acute stroke occurred due to embolisation from a 
thrombus within the left atrial appendage [35]. In two pa-
tients with spontaneous dissection of the internal carotid 
artery resulting in ischemic stroke, muscle biopsy revealed 
ragged-red fibers, severely decreased succinate dehydro-
genase and cytochrome-c-oxidase stains, and blood chemical 
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the absence of the m.3243A>G mutation, MELAS-syndrome 
was suspected [36]. Since patients with myopathy often 
develop arrhythmias, they may also require implantation of a 
device, which is associated with the risk of embolic stroke. A 
rare secondary cause of stroke in myopathies may be hyper-
viscosity resulting from immunoglobulin therapy for myosi-
tis. If patients with polymyositis receive plasma exchange 
arterial hypotension resulting in low-flow infarcts may be a 
possible side effect. 
E) Ischemic Stroke of Undetermined Etiology (Crypto-
genic Stroke) 
  Cryptogenic stroke has been reported in a number of 
patients with myopathy. Recurrent pontine stroke was re-
ported in a 4yo DMD patient. Left ventricular function was 
normal and there was no indication of atrial fibrillation [37]. 
In this case the diagnosis of DMD was uncertain since im-
munehistochemistry and genetic testing for dystrophin were 
not available at the time of diagnosis. TIA manifesting for 
two hours as aphasia and right-sided hemi-syndrome oc-
curred in a 41yo male with MD1 [38]. Though the authors 
attributed the cerebrovascular event to mitral valve prolapse 
syndrome, the proposed causal relation remains question-
able. In a patient with autosomal dominant Emery-Dreyfuss 
muscular dystrophy a fatal stroke-like episode at age 43y 
was reported [39].  
STROKE-LIKE EPISODES 
  SLEs are episodic events predominantly in MIDs, which 
characteristically spread and recur, and mimic ischemic 
stroke clinically to some extent but not on imaging studies 
[40]. So far, SLEs have been reported in MELAS-syndrome, 
MERRF-syndrome, Kearns-Sayre syndrome, Saguenay-Lac 
St. Jean cytochrome oxidase deficiency [41], and Leigh 
syndrome [42]. Interestingly, SLEs have been also reported 
in non-mitochondrial disease, such as Emery-Dreyfuss mus-
cular dystrophy [42], congenital glycosilation disorder 1a 
[43], X-linked HMSN1A [44], Jacob-Creutzfeld disease 
[45], proprionyl-CoA carboxylase deficiency [46], Sneddon 
syndrome [47], or cystinosis [48]. Most frequently SLEs 
occur in MELAS-syndrome of which they are an integral 
part of the phenotype. SLEs fundamentally differ from 
ischemic stroke also with regard to treatment, and prognosis 
(Table 5) [49]. 
1. Clinical Presentation  
  In accordance with ischemic stroke, SLEs may manifest 
as hemiparesis or aphasia. Contrary to ischemic stroke, 
stroke-like episodes may be associated with visual impair-
ment other than hemianopsia, migraine or migraine-like 
headache, seizures (non-convulsive epileptic state, repetitive 
complex partial seizures, tonic clonic seizures), ataxia, 
blurred vision, phasic alertness, amnesia, cognitive impair-
ment, dementia, confusional state, hallucinations, psychosis, 
or coma [49,50]. Frequently, presenting manifestations in-
clude headache, followed by hemianopsia, psychosis, apha-
sia, and seizures [51]. Other presenting symptoms may in-
clude gaze deviation, mental state changes, tremor, seizures, 
weakness, aphasia, or sensory, visual or hearing disturbance 
[2].  
2. Imaging 
  The equivalent of SLEs on imaging are stroke-like le-
sions (SLLs), which present as hyperintensity on T2, DWI, 
and apparent diffusion coefficient (ADC) maps, and hypop-
erfusion on perfusion weighted imaging (PWI) in the acute 
stage (Table 5) indicating vasogenic edema [52]. In most 
cases, however, there is coexistence of cytotoxic (DWI: 
hyperintense, ADC: hypointense, intracellular edema) and 
vasogenic edema (DWI: hyperintense, ADC: hyperintense, 
extracellular edema) within the same SLL [2,43], particularly 
at onset of a SLE [53]. In single cases the entire lesion may 
be hypointens on ADC. The cytotoxic edema was speculated 
to derive from gradually evolving metabolic cell death [2]. 
Table 5.  Ischemic Stroke Compared to Stroke-like Episode [2,155] 
  Ischemic stroke  Stroke-like epsiode 
Acute stage (<6h) 
  T2  Normal  Swelling, subtle hyperintensity 
  DW  Hyperintensity, vascular territory  Hyperintensity outside vascular territory 
  ADC  Hypointense    Hypo- and hyperintensity 
 PWI  Hypoperfusion  Hyperperfusion 
Subacute stage (5 days) 
 T2  Hyperintens  Hyperintens 
 DWI  Hyperintens  Hyperintens 
 ADC  Hypointensity  White  matter  hypointens 
     Cortex:  hyperintens 
Chronic stage 
 FLAIR    Hyperintensity,  atrophy Hyperintensity,  atrophy, 
 ADC  Isointens  Isointens,  hyperintensity 
 PWI    Normo-  hypoperfusion  Hypoperfusion 
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Hyperperfusion in the acute stage has been also shown by 
HMPAO-SPECT, xenon-CT, and PET studies [51,52,54,55, 
56]. In the subacute stage, T2 and DWI are hyperintense 
[51]. The ADC may be hyperintense in the cortex but hy-
pointense in the subcortical white matter (Table 5). During 
the chronic stage atrophy, cysts, or laminar cortical necrosis 
may develop, and the SLL may become hyperintense on T2 
and ADC but may show hypoperfusion on PWI (Table 5) 
[2,54,57]. Conventional angiography or MRA are usually 
normal in patients with SLEs [58]. SLLs usually persist for 
weeks or even months but may suddenly disappear even after 
years [59]. Contrary to ischemic stroke, SLLs are not con-
fined to a vascular territory. Most frequently they are located 
in the parieto-occipital region and show a characteristic dy-
namic spread to other homo- or contralateral cortical or sub-
cortical regions [2,40]. Some of the lesions disappear after a 
couple of weeks, whereas others newly develop or persist 
[2]. 
3. MR-spectroscopy 
  Hydrogen-MR-spectroscopy (H-MRS) of a SLL may 
show a reduced N-acetyl-aspartate (NAA)/creatine (Cr) ratio 
and an increased lactate-peak [51,60]. In the later stages of a 
SLL the NAA/Cr ratio may gradually increase together with 
the increase of the ADC [2,51]. In single patients the in-
crease in lactate and glucose and the decrease of NAA, glu-
tamate, or creatine is not restricted to the SLL but may occur 
ubiquitously within the brain [61].  
4. Pathogenesis 
  SLEs are usually non-ischemic events, characterized by 
increased capillary permeability, hyperperfusion, neuronal 
hyperexcitability, and neuronal loss [62]. Though the patho-
genesis of SLEs is controversial, there is largely consensus 
that SLLs represent a vasogenic edema [62]. Vasogenic 
edema may be attributable to mitochondrial microangiopa-
thy, resulting in hypoxia and capillary leakage [63]. Argu-
ments against mitochondrial angiopathy, however, are that 
the prevalence of ischemic stroke is not increased in MIDs 
with SLEs, that ischemic lesions within SLLs are rare, that 
MID patients with SLEs usually lack mitochondrial angiopa-
thy on autopsy, and that there is hyperperfusion during the 
acute stage of a SLE [2,40,55,56]. Arguments for mitochon-
drial angiopathy are that SLLs occasionally also include 
areas of cytotoxic edema and that COX-deficiency and het-
eroplasmy rates are highest in leptomeningeal or cortical 
arteries [64]. There is also one report about a MELAS patient 
who exhibited a segmental narrowing of the crural segment 
of the right posterior cerebral artery during the SLE [65]. 
According to a second hypothesis, SLLs are due to focal 
disturbance of the energy production resulting in anaerobic 
metabolism, neuronal damage, or death from acidosis [40], 
and consecutively hyperperfusion and vasogenic edema [51]. 
A third hypothesis explains SLLs by focal neuronal hyperex-
citability, demanding increased provision of energy, and 
resulting in a mismatch between demand and availability of 
energy [54,66]. An argument in favor of the “epilepsy” hy-
pothesis is that focal epileptiform discharges are recorded in 
up to 80% of the patients during a SLE [67].  
5. Treatment 
  Treatment of SLEs can be generally causal or non-causal 
(symptomatic) [49,67]. Since the pathogenic mechanism 
underlying SLEs remains elusive, a causative treatment is 
not yet available [68]. Thus, only symptomatic measures can 
be offered. Among the various symptomatic measures ap-
plied for MIDs (drugs, hemodialysis, invasive measures, 
surgical therapy, dietary measures, physiotherapy), specific 
and non-specific drug therapy is generally available for the 
management of SLEs, with the restriction that evidence for 
the effectivity of a specific or non-specific drug treatment 
has not been provided by appropriately designed studies. 
Symptomatic drug treatment of SLEs include antiepileptic 
treatment if SLEs are accompanied by seizures, analgetic 
treatment if SLEs are accompanied by headache [69], or 
anti-psychotic or sedative therapy if SLEs are dominated by 
confusion, agitation, anxiety, hyperactivity, or psychosis. 
Non-specific drug therapy includes drugs, which remove 
noxious metabolites, such as antioxidants or lactate lowering 
agents, electron donors/acceptors, alternative energy provid-
ers, cofactors, or other agents. The classification is partially 
insufficient since some agents have both an antioxidative 
effect and are effective at the same time as electron do-
nors/acceptors or cofactors of respiratory chain functions. 
Drugs with overlapping effect include riboflavin, vitamin C, 
vitamin E, or the quinones. Non-specific drug treatment of 
SLLs includes application of drug cocktails which comprise 
coenzyme Q, idebenone, L-arginine, tocopherol nicotinate, 
edaravone, prednisolone, glycerol, ATP, cytochrome-c, fla-
vin mononucleotide, thiamine diphosphate, biotin, carnitine, 
succinate, or dichloracetate in various combinations [67,70]. 
In some studies some of these agents were given in mono-
therapy, such as creatine monohydrate, cysteamine, or succi-
nate [71]. A Cochrane review of 678 abstracts, however, did 
not provide evidence that coenzyme Q, creatinemonohy-
drate, dichloracetate, or dimethylglycine are generally effec-
tive in MIDs [72]. During recent years some evidence 
emerged from Japanese studies that L-arginine has a benefi-
cial effect in SLEs [68,73,74]. According to these studies L-
arginine is applied in a dosage of 0.5g/kg body weight intra-
venously during the acute stage, followed by oral application 
thereafter. L-arginine has been shown to be effective even if 
SLEs manifest as epileptic activity [73]. Occasionally, L-
arginine is given together with steroids, glycerol and edara-
vone [74]. Even steroids in monotherapy have been shown 
beneficial in single cases [75].  
6. Outcome 
  In the majority of the cases patients recover, either to the 
level prior to the SLE or to a lower level. Depending of the 
manifestations of the SLE, the residual abnormalities may 
include one or several of the acute stage. If a SLE is associ-
ated with severe lactacidosis or intractable seizure activity, 
its outcome is potentially fatal [59]. 
CONCLUDING REMARKS 
  Ischemic stroke should be recognized as a potential mani-
festation of a myopathy. Stroke occurs most frequently in 
dystrophinopathies and myotonic dystrophy. The frequency Stroke in Myopathies  The Open Neurology Journal, 2012, Volume 6    33 
of stroke in myopathies is most likely underestimated since 
patients with myopathy are hardly systematically screened 
for cardiac involvement, since these patients do not undergo 
regular follow-ups, and since clinical deterioration in these 
patients is often attributed exclusively to the muscle disease 
itself. Stroke in myopathy may be also not expected because 
of absent classical risk factors for stroke (cryptogenic 
stroke). A strong disadvantage of most descriptions about 
myopathic patients with risk factors for stroke is the lack of a 
regular follow-up. Due to these insufficiencies myopathy 
patients should be systematically referred to the cardiologist. 
Early cardiac treatment, if indicated, may significantly im-
prove the outcome of these patients, if the measures taken 
follow the available recommendations. SLEs predominantly 
occur in patients with MIDs, most frequently in MELAS-
syndrome, and are much more frequent than ischemic stroke 
in patients with myopathy. SLEs should be early recognized 
and unequivocally delineated from ischemic stroke to initiate 
appropriate measures. Particularly if SLEs are associated 
with seizures their outcome can be strongly improved if 
adequate antiepileptic treatment is effective. Overall, neu-
rologists need to become aware of the potential association 
between myopathy and cerebrovascular events, which need 
to be clearly delineated from SLEs indicating a MID. Since 
no effective therapy is available yet, all effort should be 
directed towards research on the development of targeting, 
safe and immediately effective agents. 
ABBREVIATIONS 
ADC =  Apparent  diffusion  coefficient  maps 
CMP =  Cardiomyopathy 
DMD = Duchenne  muscular  dystrophy 
DWI  =  Diffusion weighted imaging 
EF =  Ejection  fraction 
HMSN  =  Hereditary motor and sensory neuropathy 
IVIG =  Intravenous  immunoglobulines 
LVHT  =  Left ventricular hypertrabeculation/non-
compaction 
MELAS  =  Mitochondrial encephalopathy, lactacido-
sis, and SLE-syndrome 
MID =  Mitochondrial  disorder 
MRI  =  Magnetic resonance imaging 
OAC =  Oral  anticoagulation 
PWI =  Perfusion-weighted  imaging 
SLE =  Stroke-like  episode 
SLL =  Stroke-like  lesion 
SPECT  =  Singlephoton emission computed tomo-
graphy 
TOAST  =  Trial of Org 10172 in Acute Stroke Treat-
ment 
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